金吾财讯 | 和铂医药(02142)公布，预期集团于2024年12月31日止年度的溢利将介乎人民币730万元至人民币2200万元。于报告期间，公司的现金溢利(经营现金净流入)达到人民币2.2亿元。
公告指，集团的可持续盈利能力主要由以下因素所驱动：(i)通过与全球制药公司及领先的生物技术公司持续保持战略合作伙伴关系，其独特业务模式加速增长；(ii)收入的经常性部分于2024年不断增长，包括基于平台的研究收入及随着合作项目逐渐成熟而收到来自合作伙伴的里程碑付款；以及(iii)集团有效的成本控制及高效运营管理。
另外，于2025年，公司于公开市场已合共购回814.6万股股份，总值近3000万港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.